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Abstract
Osteopenia, a condition characterised by a reduction in bone mineral content, is a common disease
of preterm babies between the tenth and sixteenth week of life. Prematurely born infants are
deprived of the intrauterine supply of minerals affecting bone mineralization.
The aetiology is multifactorial: inadequate nutrients intake (calcium, phosphorus and vitamin D), a
prolonged period of total parenteral nutrition, immobilisation and the intake of some drugs.
The diagnosis of metabolic bone disease is done by biochemical analysis: low serum levels of
phosphorus and high levels of alkaline phosphatase are suggestive of metabolic bone disease. The
disease can remain clinically silent or presents with symptoms and signs of rachitism depending on
the severity of bone demineralisation.
An early nutritional intervention can reduce both the prevalence and the severity of osteopenia.
This article reviews the pathophysiology of foetal and neonatal bone metabolism, focuses on the
nutrient requirements of premature babies and on the ways to early detect and treat osteopenia.
Background
The continuous advances in intensive care of preterm
newborns have led to a progressive decline of mortality in
Institutions where facilities and expertise for respiratory
resuscitation and respiratory distress syndrome are availa-
ble. Infant mortality dropped among all races between
1980 and 2000. The survival rate depends on the gesta-
tional age of the newborn; actually the survival rates for
very low birth weight (VLBW) are the following: for those
weighing 501 – 750 g is 56% and for the ones above 750
is 88% [1]. However, the success in the survival achieved
through an aggressive intensive care is not always paral-
leled by a subsequent fully healthy development of the
newborn.
Among the common conditions of morbidity due to the
prematurity (cerebral impairment, bronchopulmonary
dysplasia, growth failure, retinopathy...) a growing inter-
est is focusing now on the metabolic bone disease of the
prematurity (MBD), also called osteopenia of prematu-
rity.
This condition is characterised by a reduction in bone
mineral content (osteopenia), with or without rachitic
changes, and is caused by several nutritional and biome-
chanical factors.
An inadequate supply of nutrients (vitamin D, calcium
and phosphorus), a prolonged period of total parenteral
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nutrition, immobilisation and the intake of some drugs
are the main factors involved in the pathogenesis of oste-
openia [2].
The MBD usually occurs between tenth and sixteenth
week of life, but it may remain silent until severe deminer-
alisation (a reduction of BMD of 20 – 40%) occurs.
The clinical picture is various, ranging from a totally silent
condition to a clinical picture of overt rickets, with multi-
ple fractures and other alterations, when the deminerali-
sation is severe.
The purpose of this review is to focus on the recent
advances in the understanding of the bone tissue metabo-
lism and on the nutritional approach to prevent and to
treat the MBD.
Magnitude of the problem
The prevalence of MBD varies depending on gestational
age, birthweight and kind of alimentation.
It occurs in up to 55% of babies born with weight under
1000 g [3] and 23% of infants weighing < 1500 g at birth
[4] and it is especially frequent in babies under 28 weeks
of gestation. The prevalence is 40% in premature infants
who are breastfed, in contrast to 16% of those fed with a
formula designed for preterm infants and supplemented
with calcium and phosphorus [5,6].
Preterm infants with a complicated medical course and
delayed nutrition are also at high risk for MBD. Actually
in western countries there is a trend of decrease of gesta-
tional age and birthweight, so the frequency of the MBD
is expected to further increase.
Homeostasis of calcium -phosphorus
The homeostasis of calcium, phosphorus and magnesium
is fundamental for structural matrix of the bone.
Calcium and phosphate represent the major inorganic
constituents of bone. The highest amount of calcium
(99%) and of phosphorus (80%) of the whole body is in
the bone as microcrystalline apatite.
Only 1% of the total body calcium is within the extracel-
lular fluids and soft tissues. About the 50% of total serum
calcium is in the ionised form and represents the biologi-
cally active part. A further 8–10% is bounded to organic
and inorganic acid and the remaining percentage of cal-
cium is protein-bound (80% to albumin, 20% to globu-
lin).
The formation of the apatite takes place if calcium and
phosphorus are simultaneously available in optimal pro-
portions.
Also magnesium is part of the bone matrix and the 60%
of total body magnesium is in the bone.
Calcium and phosphorus homeostasis is a function of
hormones, vitamin D and dietary intake, and depends on
the intestinal absorption, skeletal accretion and reabsorp-
tion, and urinary excretion. [7]
Parathyroid hormone (PTH) is synthesised and secreted
from the parathyroid glands in response to a reduction of
serum level of ionised calcium. PTH regulates mineral
metabolism and skeletal homeostasis through its action
on target cells in bone and kidneys. It stimulates the reab-
sorption of calcium and excretion of phosphorus in the
kidney and bone reabsorption of calcium. PTH also is able
to activate the synthesis of calcitriol via stimulation of
renal 25 (OH) D3-1-alpha-hydroxylase activities.
In its active form, 1, 25(OH) 2 vitamin D, stimulates the
renal reabsorption of calcium and phosphorus. The syn-
thesis of calcitriol is inhibited by elevated serum levels of
calcium and phosphorus.
The combined actions of PTH and calcitriol maintain the
adequate concentration of calcium in the extracellular flu-
ids.
Kidneys contribute to maintain homeostasis of calcium;
urinary calcium is one third derived from diet and the
remaining from body stores, mostly bone.
Diuretics, as furosemide, increase renal calcium excretion.
Prenatal bone physiology
The amounts of minerals required for a correct accretion
of the skeleton are widely different depending on the age
of the babies.
The period of greater skeletal development is during the
intrauterine life and specifically during the last trimester.
The bone volume increases significantly with gestational
age and the high net bone formation activity is mainly due
to modelling, with a rapidly increasing trabecular thick-
ness (the trabecular thickening rate being approximately
240 times faster in the foetus than in the children).
The mineralization process is determined by synthesis of
the organic bone matrix by osteoblasts (osteoid) onto
which calcium and phosphate salts are deposited. This
process increases exponentially between 24 and 37 weeks
of gestation, reaching the 80% of mineral accretion in the
third trimester [8].
During gestation the developing fetus receives supplies of
energy, protein and mineral for adequate growth (1.2 cm/
week) and bone development.Italian Journal of Pediatrics 2009, 35:20 http://www.ijponline.net/content/35/1/20
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At term the newborn skeleton has a high physical density
(expressed as bone mass divided by bone volume).
The foetal accretion of calcium and phosphate during the
last three months of gestation is about 20 g and 10 g
respectively, which represents accretion rates of 100–120
mg/kg/day for calcium and 50–65 mg/kg/day for phos-
phate [9].
A very important role in skeletal accretion of the foetus is
played by the placenta. In fact the transfer of calcium from
the mother to the foetus through the placenta occurs via
an active transport done by the calcium pump in the basal
membrane [10]. There is a 1:4 maternal to foetal calcium
gradient [11].
Moreover, the placenta is able to convert vitamin D to
1,25-dihydrocholecalciferol which is fundamental for
transferring phosphate to the foetus [12].
The foetus is maintained hypercalcemic in a high calci-
tonin and estrogen environment which promotes the
modelling/remodelling ratio in favour of modelling and
thus increasing the endocortical bone [13].
As a result, infants born prematurely will be deprived of
the intrauterine supply of calcium and phosphorus affect-
ing bone mineralization.
It is well known that a chronic damage to the placenta
may alter the phosphate transport; this explains why
babies with intrauterine growth restriction may be osteo-
penic.
Demineralization is also observed in infants born from
mother with chorioamniositis and placental infection
[14].
Maternal dietary intake of calcium is a factor implied in
foetal bone accretion. A supplement of calcium (2 g from
before 22 weeks of gestation) to women with a low dietary
calcium intake resulted in higher bone mineral content
(BMC) of the total body in infants born at term [15].
Post-natal bone physiology
After birth the physical density of term newborns bones
decreases by 30% in the first 6 months of life [13]. This is
mostly due to an enlargement of the marrow cavity size,
which occurs faster than the increase in the cross-sectional
area of the bone cortex [16]. In term infants these postna-
tal changes are not accompanied by an increase in bone
fragility and occur because bone is exposed to different
conditions before and after birth.
First, there are important changes of hormonal environ-
ment: the reduction of maternal estrogens [17] and a post-
natal increase of PTH level mainly due to a reduction of
the calcium supply by the placenta [18].
As the serum calcium levels falls in the first day of life,
PTH secretion is stimulated. During this transition the
response of the parathyroid gland to falling levels of ion-
ised calcium is blunted, as emphasized in a recent review
article [19]. This finally results in a physiological nadir in
neonatal serum calcium levels within the first 48 hours of
life. Of note, PTH level is still within the normal range for
term babies or adult, but represents a decrease from foetal
levels.
Many factors affect calcium absorption including the
maternal vitamin D status, solubility and bioavailability
of calcium salts, quality and quantity of calcium, amount
and type of lipids and, obviously, gut function.
Calcium absorption from the intestine occurs both pas-
sively and through a vitamin-D dependent active trans-
port mechanism. In a newly born preterm the low mineral
content of human milk associated with a poorly efficient
absorption of the developing gut determine a net reduc-
tion of calcium and phosphorus supply.
Absorption of phosphorus takes place in the jejunum and
depends on the dietary intake. The phosphorus supply
regulates calcium absorption and retention: the higher is
the phosphorus content of the diet, the higher is the cal-
cium retention. However, an excessive amount of one
decreases the absorption of the other.
Moreover, while in utero fetus experiments mechanical
stimulation by kicking against the uterine wall, this kind
of training is missing during the extrauterine life since pre-
term babies usually stay in the incubator [20,21]. Inactiv-
ity due to immobilisation stimulates bone reabsorption
by osteoclasts and urinary calcium excretion; furthermore
the reduced muscle activity prevents the addition of new
bone tissue [22]. Conditio sine qua non for the physical
activity to be beneficial is that an adequate mineral intake
is guaranteed [23].
The figure 1 shows that during the third trimester of gesta-
tion, bone mineral apparent density (BMAD) increases at
a faster rate in utero (term infants) than ex utero (preterm
infants) according to gestational age.
BMAD is an estimation of volumetric BMD (g/cm3) calcu-
lated as bone mineral content/bone area (BMC/BA). The
figure 1 also shows that there is a sharp reduction in
BMAD in neonatal age followed by a stabilization that
lasts all the first year of life ("black triangles"). A similar
event occurs in preterm babies: from birth to the term,
mineral retention sharply diminishes comparing with the
foetal life, while the skeletal growth remains high. ThisItalian Journal of Pediatrics 2009, 35:20 http://www.ijponline.net/content/35/1/20
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leads to a reduction of bone density ("white squares"). A
catch up mineralization occurs after discharge of VLBW so
BMC spontaneously improves ("white rhombs").
Among the other pathogenic factors, also problems
related to inadequate supply of calcium to babies, which
require parenteral nutrition and interference of several
drugs, may contribute to determine preterm osteopenia
with an increasing risk of bones fractures.
The drugs mostly implied in pathogenesis of MBD include
steroids, methylxanthines and diuretics. They stimulate
osteoclasts activation, decrease calcium absorption,
reduce osteoblasts proliferation and increase calcium
renal excretion and hence increase the risk of poor bone
mineralization [24-26].
Neonatal mineral requirements
The requirements of calcium and phosphorus are based
on demands for matching intrauterine bone mineral
accretion rates.
Supplying calcium and phosphorus in parenteral nutri-
tion is a challenge because of limited solubility of these
two minerals. Calcium and phosphorus's solubility in
nutrition admixtures depends on temperature, type and
concentration of aminoacid, glucose concentration, pH,
type and concentration of calcium salts, and presence of
lipid and so on...
In parenteral nutrition calcium is administered as inor-
ganic salt and phosphorus may be administered as inor-
ganic sodium and potassium phosphate or sodium-
glucose phosphate or glycerolphosphate, which are quite
soluble in water.
The addition of cystein to lower pH of the parenteral
admixtures improves the solubility of calcium and phos-
phorus.
For all such reasons it is not possible to supply these min-
erals according to the physiologic requirements of the pre-
term to reach an adequate bone mineralization.
In the transition period, most of VLBW neonates receive
full or partial parenteral nutrition with the goal to main-
tain normal levels of calcium and phosphorus. Hypocal-
caemia, in fact, is a common event during the first days of
Physiological evolution of DEXA apparent bone mineral density during the last trimester of gestation (filled squares) and during  the first year of life in healthy term infants (upper triangles) compared to that observed in preterm infants (open squares and  lower triangles) Figure 1
Physiological evolution of DEXA apparent bone mineral density during the last trimester of gestation (filled 
squares) and during the first year of life in healthy term infants (upper triangles) compared to that observed in 
preterm infants (open squares and lower triangles). (With permission from Ref [12]).Italian Journal of Pediatrics 2009, 35:20 http://www.ijponline.net/content/35/1/20
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life because of the sharp decrease of the calcium supply by
the placenta and the delayed release of PTH due to the
immature response of the parathyroid glands.
Parenteral administration of 50–75 mg of calcium/kg/day
can prevent early neonatal hypocalcaemia in preterm
infants.
Through the parenteral administration of calcium and
phosphorus (40–70 mg/kg/day and of 25–45 mg/kg/day
respectively) it is possible to achieve 60 – 70% of intrau-
terine mineralization [27]. The best calcium to phospho-
rus ratio for bone mineralization is 1.7:1 [28-30].
In preterm babies receiving parenteral nutrition only lim-
ited amounts of vitamin D are required since calcium is
given by vein and there is no need of calcitriol to facilitate
the intestinal uptake.
Moreover only the parent compound needs to be admin-
istered since the preterm infant is able to hydroxylate the
inactive form to the active one since the 24th week of ges-
tation. It is now generally accepted the daily recom-
mended dose of vitamin D is 400 U.I./day [18].
For the transitional period, when infants are weaned from
parenteral nutrition to the enteral one, the aim usually is
to maintain an adequate serum level of calcium and phos-
phorus. However the serum level of calcium is not a good
marker of adequacy of calcium intake since the level is
maintained stable at the expense of the bone. Therefore
the clinicians should be aware that a normal serum level
of both calcium and phosphorus are not guarantee for an
adequate whole body accretion as in intrauterine life.
The enteral administration of calcium is fraught with
many problems as regards the calcium bioavailability.
Vomiting, large gastric aspirates, constipation and
abdominal distension are quite common in preterm
babies and the gut absorption capacity is impaired due to
the immaturity of the gastrointestinal mucosa.
Calcium absorption depends on vitamin D status, solubil-
ity of calcium salts, quality and quantity of lipid intake.
Moreover, in preterm babies, vitamin D demands are
influenced by body contents at birth which depends on
the duration of gestation and maternal vitamin status.
Current estimates of requirements for calcium, phospho-
rus and vitamin D in growing premature infants vary
among international sources of recommendations [31-
34] (Table 1).
The human milk content is inadequate for preterm
requirements since the content of calcium and phospho-
rus in preterm human milk is 31 mg/100 kcal and 20 mg/
100 kcal [18] while the Life Science Research Office [31]
suggests, for premature formulas, a dose approximately
4–6 times higher (123 to 185 mg Ca/100 kcal and 80 to
110 mg P/100 kcal). Even when VLBW are fed at high
feeding volumes (180–200 mL/Kg), assuming calcium
and phosphorus absorption of 70% and 80% respectively,
this would provide only one-third of the in utero level of
absorbed calcium and phosphorus [6]. Formula milk is
richer in calcium and phosphorus than human one, but
bioavailability is quite different. In formula fed infants,
calcium absorption is usually less than with human milk,
ranging from 35 to 60% of the intake. Hence the human
milk intake has to be promoted, but a fortification with
mineral and protein fortifier is necessary to achieve ade-
quate nutrient intake.
With the current human milk fortifiers, containing highly
soluble calcium glycerolphosphate, calcium retention
reaches a level of 90 mg/kg/day (88% of the overall
intake).
However the new human milk fortifiers available in the
market still do not allow intakes of calcium comparable
with the values achieved during the last trimester of gesta-
tion (100–120 mg/kg/day) which are considered the tar-
get mineral accretion for preterm infants, nevertheless the
use of multinutrient fortification of human milk for pre-
mature infants is currently recommended.
A Cochrane systematic review and metaanalysis of human
milk fortifiers, which however included studies on chil-
dren who were not extremely preterm (the class at major
Table 1: Minerals and vitamin D recommended intakes in growing preterm infants.
Requirements ESPGAN [32] LSRO [31] Atkinson [33] Rigo [34]
1987 2002 2005 2007
Calcium (mg/kg/day) 70–140 150–220 120–200 100–160
Phosphorus (mg/kg/day) 50–90 100–130 60–140 60–90
Vitamin D (I.U./day) 800–1600 200–1000 800–1000
(I.U./kg/day) 90–225 150–400Italian Journal of Pediatrics 2009, 35:20 http://www.ijponline.net/content/35/1/20
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risk) stated that the effects on bone mineralization were
not conclusive [35].
Finally, it must be noted that high calcium supplementa-
tion of milk is not well tolerated; it is associated with high
faecal calcium, prolonged gastrointestinal transit time and
impaired fat absorption. All these effects are potential risk
factors for developing necrotizing enterocolitis.
(See table 1)
Clinical features and diagnosis
MBD remains silent until a severe demineralisation
occurs. The most evident clinical findings of osteopenia
are deformity of the skull (diastasis of the suture, enlarge-
ment of the sagittal fontanelle and frontal bosses, crani-
otabe), thickening of the chondrocostal junctions and of
the wrists, rib and long bones fractures. Softening and/or
fractures of the ribs can cause pulmonary changes and res-
piratory distress, typically between 5 and 11 weeks of age
[36].
Diagnosis of osteopenia is mainly done by serum analy-
sis. Biochemically osteopenia is characterised by low
serum levels of phosphorus and by an increase in serum
levels of alkaline phosphatase that can reach values 5
times higher than the upper reference range used for
adults [37]. It is useful dosing the isoenzimes of alkaline
phosphatase since this enzyme is synthetised also by the
liver and by the gut.
Backstrom and colleagues suggested that serum alkaline
phosphatase levels higher than 900 U.I/l associated with
a serum phosphate level lower than 1.8 mmol/l have a
diagnostic sensitivity of 100% and specificity of 70% [38].
However the opinions in literature about the reliability of
alkaline phosphatase to predict the status of bone miner-
alization are still conflicting [39,40]
Serum level of calcium is usually within the normal range
due to effects of PTH on the bone. Low concentrations of
calcium and phosphorus in the urine suggest an inade-
quate intake. This is manly due by an increase of the tubu-
lar reabsorption of phosphate because of the low dietary
intake and by an increase of PTH level that stimulates the
reabsorption of calcium. Markers of nutritional status
should be assessed baseline, and then weekly during the
initial phase; once the newborn is stable, assessment must
be done at the starting of total enteral nutrition and suc-
cessively every 2–3 weeks. If MBD is diagnosed and nutri-
tional supplementation is started, a periodic assessment
of laboratory data is necessary to evaluate the response to
treatment also when babies are discharged from hospital.
The key clinical goal is to maintain normocalcemia and
normophosphatemia and to avoid an excessive calciuria.
Once levels of ALP, calcium and phosphorus normalize,
serum analysis can be performed monthly up to 6 months
of age and then every 3 months.
X-rays examination may show fractures, thin bones and
other alterations as reduction of thickness of the cortical,
enlargement of the epiphysis, irregular border between
growth cartilage and bony metaphysis [41].
Dual energy X-ray absorbitometry (DEXA) is able to deter-
mine the bone mass content of neonates and can predict
the risk of fractures [39,42] since it is sensitive in detecting
small changes in BMC and BMD. Its use is now validated
in neonates both term and preterm ones.
DEXA reflects most accurately the state of bone minerali-
zation in preterm infants [43] but the examination
involves radiations for the baby and the device is not port-
able.
Quantitative ultrasound is simpler than DEXA and is non-
invasive; it can be used bedside without moving the baby.
Reference values are now available for infants. Quantita-
tive ultrasound gives information about structure of the
bone and about bone density [44].
Osteopenia has a good prognosis since the disease is self-
resolving, provided that calcium, phosphates and vitamin
D are appropriately administered to the babies.
It is still controversial the need for high calcium and phos-
phorus intakes in preterm infants after hospital discharge.
Few data are available about the optimal length, quantity
and methods of providing supplemental minerals for pre-
term infants who are in stable growth.
There are studies that show increased bone mineral mass
in infants who receive formulas containing more minerals
that the traditional ones up to 9 months [45,46].
It has been shown, with studies assessing bone minerali-
zation with quantitative ultrasound and DEXA, that pre-
term infants show a catch-up mineralization for the first
year of life. There is no difference in late childhood of
bone mineralization between term and ex-preterm infants
[47] even though the biochemical evidence of metabolic
bone disease during the neonatal period may have a long-
term stunting effect which continues up to 12 years later.
A recent study published on Journal of Perinatology [48]
stated that children who were born prematurely with birthItalian Journal of Pediatrics 2009, 35:20 http://www.ijponline.net/content/35/1/20
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weights less than 1.5 kg tend to be significantly smaller for
age and have lower lumbar spinal bone mineral content
and density compared with children born at term gesta-
tion.
The long duration of this complication provides further
rationale for implementing any practice that can prevent
this condition [49].
In the case of BMD of prematurity nutrition is both ther-
apy and prevention. An adequate intake of minerals and
of vitamin D, with breast milk fortifier or formula with a
content of minerals suitable for preterm infant's require-
ments, are necessary for a correct bone mineralization.
A regular physical stimulation, when the preterm infant is
clinically stable and is receiving adequate doses of cal-
cium, phosphate and vitamin D, should also be included
in the standard preventive approach.
Conclusion
An adequate nutritional intake of calcium, phosphorus
and vitamin D and passive physical exercise may prevent
abnormal bone-remodelling activity during first weeks of
life and may optimize growth potential of preterm
infants. It is important to recognize the biochemical signs
of osteopenia in an early stage in order to be able to pre-
cociously implement the dietary intake and reduce the
risk of bones fractures. The determination of alkaline
phosphatase and of phosphoraemia seems to be useful in
assessing the risk of metabolic bone disease and serum
analysis need to be performed periodically in order to
assess response to nutritional treatment. Through DEXA
and quantitative ultrasound it is also possible to deter-
mine the state of bone mineralization and therefore to
plan a nutritional intervention.
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